Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CEO Richard Nolan Townsend sold 3,345 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $4.95, for a total transaction of $16,557.75. Following the sale, the chief executive officer owned 374,472 shares in the company, valued at $1,853,636.40. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Richard Nolan Townsend also recently made the following trade(s):
- On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.48, for a total value of $116,242.56.
Lexeo Therapeutics Stock Up 8.9%
LXEO stock opened at $5.37 on Thursday. The business has a 50 day moving average price of $4.70 and a 200 day moving average price of $5.56. The stock has a market cap of $440.61 million, a price-to-earnings ratio of -4.67 and a beta of 1.46. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $32,000. Allworth Financial LP lifted its stake in Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Lexeo Therapeutics in the fourth quarter worth about $37,000. Finally, California State Teachers Retirement System boosted its stake in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares during the period. 60.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on LXEO. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. reduced their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Finally, Wall Street Zen downgraded Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $18.75.
Check Out Our Latest Report on Lexeo Therapeutics
About Lexeo Therapeutics
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Featured Articles
- Five stocks we like better than Lexeo Therapeutics
- One Platform, Every Ailment: Hinge Health’s Gamble
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
